On Thursday, April 10, 2025 at 4:00 pm during Oral Poster Presentation: Research 3 at NKF SCM25, Dr. Wolfgang Winkelmayer will present a poster titled “Vadadustat for Treatment of Anemia in Older vs ...

According to the results of a single-center, prospective, crossover study, darbepoetin alfa—a hyperglycosylated, and therefore longer-acting, derivative of epoetin—is a more effective ...

All three erythropoiesis-stimulating agents — the two recombinant erythropoietins (Epogen and Procrit) and the closely related protein darbepoetin alfa (Aranesp) — are FDA-approved ...

Darbepoetin alfa 10mcg/0.4mL, 25mcg/0.42mL, 40mcg/0.4mL, 60mcg/0.3mL, 100mcg/0.5mL, 150mcg/0.3mL, 200mcg/0.4mL, 300mcg/0.6mL, 500mcg/mL; per prefilled syringe; for IV ...

When he worked for the California-based biotechnology company Amgen in the 1990s, Steve Elliott was instrumental in the development of darbepoetin alfa (Aranesp), a drug to treat anemia in people with ...

The seven REMS-requiring drugs for which a formal policy or procedure was found to be lacking were ambrisentan, buprenorphine–naloxone, darbepoetin alfa, epoetin alfa, oxycodone controlled ...

Cardiovascular Risk in Patients With DD-CKD Randomized to Vadadustat vs Darbepoetin Alfa With or Without Cardiovascular Disease: Poster: G-284 Vadadustat for Treatment of Anemia in Older vs ...